Earnings
Unum's Disability Claims Jumped 10% Above Plan, And Management Can't Say If It Lasts
The insurer's group disability benefit ratio hit 70.6% from 61.3% a year earlier, and executives would not call the spike cyclical or structural.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
The insurer's group disability benefit ratio hit 70.6% from 61.3% a year earlier, and executives would not call the spike cyclical or structural.
Earnings
CEO Matt Kapusta calls the study an ethical obligation, with an FDA decision on AMT-130 targeted for May 1, 2027.
SEC Filings
Shaun Mara and Ken Plunk join the audit and finance committees on Nov. 18, as the baker's board grows to 10 members.
SEC Filings
Patients given two step-up doses of CLN-049 had a 26% rate of cytokine release syndrome, versus 36% on one step-up dose.
Deals
Shoals CEO Brandon Moss would run the merged company, and ARRAY committed to redeem $317.5 million of preferred stock.
SEC Filings
Cencora recast fiscal 2026 and 2025 results under the structure it will use from fiscal 2027, with total revenue of $337.4 billion.
Earnings
The chief medical officer says the 63-patient trial is powered at close to 90%, with topline data due in the second quarter of 2027.
Earnings
Large customers renewed earlier than expected, trading bigger commitments for lower prices, CEO Olivier Pomel told analysts.
Earnings
CEO David Joyner says the plan to separate stores from insurance comes from strength, as CVS also raised its 2026 adjusted EPS outlook to at least $8.20.
Earnings
Niraj Shah says the home category is flat and Wayfair's growth is its own doing, with a fourth-quarter adjusted EBITDA margin guided to 6% to 7%.
Earnings
Trimble held revenue guidance and nudged up its earnings forecast, with farm positioning and bundled offers dragging on recurring revenue.
Earnings
LivaNova's CFO blames coding and reimbursement confusion for slower growth in nerve-stimulation sleep apnea therapy, and raised 2026 guidance to 9% to 10%.